重度主动脉瓣狭窄TAVR患者中转甲状腺素心脏淀粉样变的患病率与预测因素
该前瞻性研究对151例接受TAVR的重度症状性主动脉瓣狭窄老年患者行99mTc-PYP心脏闪烁扫描,发现16%筛查阳性为ATTR-CA。ATTR-CA患者表现为低流速低梯度、射血分数轻度降低的严重AS表型,二尖瓣环组织多普勒平均S'≤6 cm/s对阳性扫描具有100%敏感性。
要点
- 重度AS行TAVR的老年患者中ATTR-CA患病率为16%。
- ATTR-CA与低流速低梯度、射血分数轻度降低的严重AS表型相关。
- 二尖瓣环组织多普勒平均S'≤6 cm/s可敏感提示需行99mTc-PYP扫描。
核心结论
- 在接受TAVR的重度钙化性AS患者中,ATTR-CA患病率为16%,并与低流速低梯度伴射血分数轻度降低的严重AS表型相关。
- 二尖瓣环组织多普勒平均S'≤6 cm/s可能是一个敏感指标,应促使行确认性99mTc-PYP扫描及后续ATTR-CA检测。
研究设计与样本
- 前瞻性队列研究,对接受TAVR的患者行99mTc-PYP心脏闪烁扫描筛查ATTR-CA,并完成经胸超声心动图与斑点应变成像。
- 共纳入151例患者,平均年龄84±6岁,68%为男性。
主要发现
- 16%(n=24)患者经99mTc-PYP闪烁扫描筛查阳性为ATTR-CA。
- 与无ATTR-CA者相比,ATTR-CA患者室间隔更厚(1.3 vs. 1.1 cm,P=0.007)、左室质量指数更高(130 vs. 98 g/m2,P=0.002)、每搏量指数更低(30 vs. 36 mL/m2,P=0.009)。
- ATTR-CA患者舒张功能障碍更重:E/A比值更高(2.3 vs. 0.9,P=0.001)、减速时间更短(176 vs. 257 ms,P<0.0001)。
- ATTR-CA患者收缩功能受损:射血分数更低(48% vs. 56%,P=0.011)、心肌收缩分数更低(26 vs. 41,P<0.0001)、二尖瓣环侧壁与间隔组织多普勒S'平均值更低(4.0 vs. 6.6 cm/s,P<0.0001)。
- ATTR-CA患者整体纵向应变更差(-12 vs. -16%,P=0.007),但相对心尖纵向应变两组相同(0.98 vs. 0.98,P=0.991)。
关键数值与推荐
- 多变量逻辑回归中,平均S'是ATTR-CA的最佳预测指标(每降低1 cm/s的比值比16.67,AUC 0.96,95%CI 0.90-0.99,P=0.002)。
- 平均S'≤6 cm/s对预测99mTc-PYP淀粉样扫描阳性具有100%敏感性。
临床怎么用
- 对重度AS拟行TAVR的老年患者,应关注二尖瓣环组织多普勒平均S',若≤6 cm/s应行99mTc-PYP扫描以筛查ATTR-CA。
- ATTR-CA患者常表现为低流速低梯度伴射血分数轻度降低的严重AS表型,超声参数有助于识别。
局限性
- 需要前瞻性评估ATTR-CA患者与无ATTR-CA患者TAVR后的结局。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS: Transthyretin cardiac amyloidosis (ATTR-CA) has been reported in patients with aortic stenosis (AS) but its prevalence and phenotype are not known. We examine elderly patients with severe symptomatic AS undergoing transcatheter aortic valve replacement (TAVR) and determine the prevalence and phenotype of ATTR-CA non-invasively. METHODS AND RESULTS: We performed technetium-99m pyrophosphate (99mTc-PYP) cardiac scintigraphy prospectively on patients who underwent TAVR, to screen for ATTR-CA. Transthoracic echocardiography and speckle-strain imaging were performed. We assessed the association of several parameters with ATTR-CA using multivariable logistic regression and constructed receiver operating curves to evaluate the best predictors of ATTR-CA. Among 151 patients (mean age 84 ± 6 years, 68% men), 16% (n = 24) screened positive for ATTR-CA with 99mTc-PYP scintigraphy. Compared with patients without ATTR-CA, ATTR-CA patients had a thicker interventricular septum (1.3 vs. 1.1 cm, P = 0.007), higher left ventricular (LV) mass index (130 vs. 98 g/m2, P = 0.002), and lower stroke volume index (30 vs. 36 mL/m2, P = 0.009). ATTR-CA patients had advanced diastolic dysfunction with higher E/A ratio (2.3 vs. 0.9, P = 0.001) and lower deceleration time (176 vs. 257 ms, P < 0.0001); impairment in systolic function with lower ejection fraction (48% vs. 56%, P = 0.011), myocardial contraction fraction (26 vs. 41, P < 0.0001), and average of lateral and septal mitral annular tissue Doppler S' (4.0 vs. 6.6 cm/s, P < 0.0001). While ATTR-CA patients had more impaired global longitudinal strain (-12 vs. -16%, P = 0.007), relative apical longitudinal strain was the same regardless of ATTR-CA diagnosis (0.98 vs. 0.98, P = 0.991). Average S' best predicted ATTR-CA in multivariable logistic regression (odds ratio 16.67 per 1 cm/s decrease with AUC 0.96, 95% confidence interval 0.90-0.99, P = 0.002) with a value ≤6 conferring 100% sensitivity for predicting a positive 99mTc-PYP amyloid scan. CONCLUSIONS: Transthyretin cardiac amyloidosis is prevalent in 16% of patients with severe calcific AS undergoing TAVR and is associated with a severe AS phenotype of low-flow low-gradient with mildly reduced ejection fraction. Average tissue Doppler mitral annular S' of < 6 cm/s may be a sensitive measure that should prompt a confirmatory 99mTc-PYP scan and subsequent testing for ATTR-CA. Prospective assessment of outcomes after TAVR is needed in patients with and without ATTR-CA.
引用
- Castaño A, Narotsky DL, Hamid N, et al. Unveiling transthyretin cardiac amyloidosis and its predictors among elderly patients with severe aortic stenosis undergoing transcatheter aortic valve replacement. Eur Heart J. 2017. PMID: 29019612. doi:10.1093/eurheartj/ehx350
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。